“Mitomycin gel, or Jelmyto, is the first agent that gives us a chance to be able to treat these low-grade upper tract cancers of the ureter and the kidney and prevent their recurrence,” says Munver.
Ravi Munver, MD, vice chairman, chief, Minimally Invasive and Robotic Urologic Surgery, Department of Urology, Hackensack University Medical Center, discusses the treatment breakthrough of mitomycin gel (Jelmyto) as a therapy for patients with low-grade upper tract urothelial carcinoma.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.